Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02426125 | A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer(RANGE) | completed | Phase 3 | 530 | Eli Lilly and CompanyINDUSTRY | 23 | Aug 21, 2023 | clinicaltrials |
| NCT00352079 | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | terminated | Phase 3 | 41 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02449239 | Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG(VISTA) | completed | Phase 3 | 133 | Sesen Bio, Inc.INDUSTRY | 2 | Jul 24, 2023 | clinicaltrials |
| NCT00003376 | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | completed | Phase 3 | 330 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02948543 | Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer(BCG+MM) | unknown | Phase 3 | 501 | University of SydneyOTHER | 2 | Jun 18, 2023 | clinicaltrials |
| NCT00003701 | Combination Chemotherapy in Treating Patients With Bladder Cancer | completed | Phase 3 | 490 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02695771 | The Bladder Instillation Comparison Study(BIC) | completed | Phase 3 | 101 | Corewell Health WestOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT01675219 | Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9) | unknown | Phase 3 | 400 | Turku University HospitalOTHER_GOV | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05810623 | Single-Dose Intravesical Chemotherapy After Diagnostic URS(MINERVA) | not yet recruiting | Phase 3 | 394 | David D'AndreaOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03718754 | En-bloc vs Conventional Resection of Primary Bladder Tumor(eBLOC) | completed | Phase 3 | 384 | David D'AndreaOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT01869413 | Tranexamic Acid During Cystectomy Trial (TACT)(TACT) | completed | Phase 2 / Phase 3 | 354 | Ottawa Hospital Research InstituteOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05392634 | Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery(MACS) | unknown | Phase 3 | 98 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT04947059 | Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)(GENSA) | recruiting | Phase 3 | 180 | University of ThessalyOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | terminated | Phase 3 | 62 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 27, 2021 | clinicaltrials |
| NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) | terminated | Phase 3 | 118 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT04939194 | Fast Track Protocol After Radical Cystectomy and Urinary Diversion: A Randomised Controlled Trial. | unknown | Phase 3 | 200 | Mansoura UniversityOTHER | 1 | Jun 25, 2021 | clinicaltrials |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer(BOND) | terminated | Phase 2 / Phase 3 | 22 | CG Oncology, Inc.INDUSTRY | 1 | Apr 14, 2021 | clinicaltrials |
| NCT03664869 | Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer(FB10) | unknown | Phase 3 | 300 | Turku University HospitalOTHER_GOV | 1 | Apr 1, 2021 | clinicaltrials |
| NCT00461591 | Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) | completed | Phase 3 | 802 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02818725 | I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations(GETUG-AFU19) | completed | Phase 3 | 133 | UNICANCEROTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT02793128 | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study(Olympus) | completed | Phase 3 | 71 | UroGen Pharma Ltd.INDUSTRY | 2 | Dec 22, 2020 | clinicaltrials |
| NCT01993979 | A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)(POUT) | unknown | Phase 3 | 261 | Institute of Cancer Research, United KingdomOTHER | 1 | May 4, 2020 | clinicaltrials |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA) | terminated | Phase 3 | 5 | Medical Enterprises Ltd.INDUSTRY | 1 | Apr 15, 2020 | clinicaltrials |
| NCT01076387 | Randomized Trial Comparing Robotic and Open Radical Cystectomy | completed | Phase 3 | 124 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT00445601 | S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | completed | Phase 3 | 406 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02660190 | Photodynamic Diagnosis (PDD) in Flexible Cystoscopy(DaBlaCa-11) | completed | Phase 3 | 696 | Jørgen Bjerggaard JensenOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | completed | Phase 3 | 931 | Hoffmann-La RocheINDUSTRY | 29 | Aug 1, 2019 | clinicaltrials |
| NCT00003779 | Biological Therapy in Treating Patients With Bladder Cancer | completed | Phase 3 | 40 | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT03298958 | Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer | withdrawn | Phase 3 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT02355886 | Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy | completed | Phase 2 / Phase 3 | 25 | University of WashingtonOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT02438852 | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer | withdrawn | Phase 3 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00867347 | Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer | completed | Phase 3 | 45 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT00004154 | Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 3 | 111 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT02560584 | A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting | completed | Phase 3 | 304 | PhotocureINDUSTRY | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02471495 | RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE) | withdrawn | Phase 3 | 0 | Medical Enterprises Europe B.V.INDUSTRY | 0 | May 7, 2018 | clinicaltrials |
| NCT03427034 | Assessment of BladderLight SurvEILlance(ABSEIL) | unknown | Phase 2 / Phase 3 | 2,100 | Cambridge University Hospitals NHS Foundation TrustOTHER | 0 | Feb 9, 2018 | clinicaltrials |
| NCT01469221 | Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) | terminated | Phase 3 | 47 | Spectrum Pharmaceuticals, IncINDUSTRY | 4 | Dec 15, 2017 | clinicaltrials |
| NCT00598806 | Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) | completed | Phase 3 | 812 | Spectrum Pharmaceuticals, IncINDUSTRY | 3 | Nov 13, 2017 | clinicaltrials |
| NCT03296306 | Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma(FOCUS) | unknown | Phase 3 | 330 | Asan Medical CenterOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01200992 | Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer(EMBARC-RF) | terminated | Phase 3 | 84 | Bioniche Life Sciences Inc.INDUSTRY | 6 | Aug 24, 2017 | clinicaltrials |
| NCT00330499 | Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. | completed | Phase 3 | 67 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Jul 12, 2017 | clinicaltrials |
| NCT03193788 | Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy(PREMIER) | unknown | Phase 3 | 74 | Asan Medical CenterOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT00005047 | 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer | terminated | Phase 3 | 521 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 8, 2017 | clinicaltrials |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | terminated | Phase 2 / Phase 3 | 51 | Nippon Kayaku Co., Ltd.INDUSTRY | 2 | Mar 29, 2017 | clinicaltrials |
| NCT01410565 | Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer | terminated | Phase 3 | 66 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Dec 13, 2016 | clinicaltrials |
| NCT02951078 | A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer | unknown | Phase 3 | 172 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT00028756 | Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium | completed | Phase 3 | 285 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Aug 2, 2016 | clinicaltrials |
| NCT00406068 | Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer | completed | Phase 2 / Phase 3 | 129 | Bioniche Life Sciences Inc.INDUSTRY | 2 | Jul 28, 2016 | clinicaltrials |
| NCT00014534 | Combination Chemotherapy in Treating Patients With Bladder Cancer | completed | Phase 3 | 42 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00003623 | High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer | completed | Phase 3 | 21 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 13, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2023source: clinicaltrials